Actelion Receives Frost & Sullivan 2007 North American Pulmonary Arterial Hypertension Market Leadership Award.PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif. -- Frost & Sullivan today announced that it has awarded the 2007 North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Pulmonary Arterial Hypertension (PAH PAH, PAHA aminohippuric acid. PAH abbr. para-aminohippuric acid PAH 1 Polycyclic aromatic hydrocarbon, see there 2. Pulmonary artery HTN ) Market Leadership of the Year Award to Actelion Pharmaceuticals US, Inc. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Frost & Sullivan's research, Actelion is the key leader in the U.S. PAH market. Actelion's product Tracleer(R) (bosentan), an orally available dual endothelin receptor antagonist A endothelin receptor antagonist (ERA) is a drug which blocks endothelin receptors. Two main kinds of ERAs exist:
"Actelion has been at the forefront of PAH research and development over the past decade, and continues to be the market leader," said Frost & Sullivan research analyst Barath Shankar S. "This year's CoTherix acquisition makes Actelion a company with two marketed PAH therapies in the U.S., providing a continued competitive advantage in this growing market." The Frost & Sullivan Award A Sullivan Award may refer to:
The compounded annualized rate of growth of a company's revenues, earnings, dividends, or other figures. Notes: Remember, historically high growth rates don't always mean a high rate of growth looking into the future. , profitability, and market and technology innovation. Actelion was selected as the 2007 award recipient based on the company's commitment to improving patient care through drug discovery, which has led to two product launches and a strong product pipeline in the ten years since its founding; its global infrastructure, which supports commercialization of new therapies and expansion of existing therapies; and market expansion through inorganic growth Inorganic growth is the rate of business, sales expansion etc. by increasing output and business reach by acquring new businesses by way of mergers, acquisitions and take-overs. , evidenced by the recent acquisition of CoTherix. "We've been aggressively developing important new therapies for PAH and actively raising awareness Raising awareness is a common phrase advocacy groups use to justify a particular event, brochure or even the entire organization. Raising awareness refers to alerting the general public that a certain issue exists and should be approached the way the group desires. of this devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. disease with physicians and patients for a decade," said Shal Jacobovitz, President of Actelion Pharmaceuticals US. "This award recognizes our leadership in the PAH community, and we are committed to maintaining this level of innovation and most importantly to continuing to improve the lives of patients with PAH." For more information about Frost & Sullivan's Best Practices Awards, visit www.awards.frost.com. About Actelion Pharmaceuticals Actelion Pharmaceuticals has pioneered research and development in the pulmonary arterial hypertension (PAH) disease area. More than 40,000 PAH patients have been prescribed Actelion's product Tracleer(R) (bosentan), an orally available dual endothelin receptor antagonist for patients with World Health Organization (WHO) Class III or IV PAH. Tracleer was approved in 2001 as the first oral treatment for PAH, and is currently approved in the U.S., the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community , and other markets worldwide. In January 2007, Actelion acquired CoTherix, Inc., whose product Ventavis(R) is approved and marketed in the United States for the treatment of patients with WHO Class III or IV PAH. About Frost & Sullivan Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.awards.frost.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion